RxDoctor Payments DataLook up a doctor →

Darush Rahmani, DO

Rheumatology · Round Rock, TXNPI 1598714495

Payments from drug & device makers

$535,733in general payments, 2019–2025

Across 107 payments — averaging $5006.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$515K
  • Swing Therapeutics, Inc.$19K
  • UCB, Inc.$325
  • AbbVie$241
  • Welch Allyn$186
  • Johnson & Johnson$99
  • plus $189 from 6 others

What the payments were for

  • Food & beverage$81578%
  • Education$394%
  • Other$18618%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$535,733 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$1,915,517
Medicare patients
421
Services billed
148,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept65$591,988
Humira(Cf) PenAdalimumab46$431,807
Teriparatide45$119,838
Cosentyx Sensoready PenSecukinumab17$117,791
KevzaraSarilumab27$116,205
OtezlaApremilast15$115,459
Cosentyx Sensoready (2 Pens)Secukinumab14$100,527
Humira(Cf)Adalimumab13$88,550
ActemraTocilizumab31$81,439
ForteoTeriparatide12$49,926
OlumiantBaricitinib11$29,537
Hydroxychloroquine Sulfate267$12,192
MethotrexateMethotrexate Sodium258$9,415
Febuxostat29$6,599
Mycophenolate Mofetil51$5,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$87$115,45915 claims
AbbVieHumira(Cf)$241$88,55013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →